(S)-1-(4-((2-(2-Aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one
CAS: 1032754-93-0
Ref. 3D-FA34129
1mg | Ausgelaufen | ||
2mg | Ausgelaufen | ||
5mg | Ausgelaufen | ||
10mg | Ausgelaufen | ||
25mg | Ausgelaufen |
Produktinformation
- Gdc-0980
- Gne 390
- (S)-1-(4-((2-(2-aMinopyriMidin-5-yl)-7-Methyl-4-Morpholinothieno[3,2-d]pyriMidin-6-yl)Methyl)piperazin-1-yl)-2-hydroxypropan-1-one
- Gdc-0980 (Rg7422)
- Apitolisib
- (2S)-1-(4-{[2-(2-Amino-5-pyrimidinyl)-7-methyl-4-(4-morpholinyl)thieno[3,2-d]pyrimidin-6-yl]methyl}-1-piperazinyl)-2-hydroxy-1-propanone
(S)-1-(4-((2-(2-Aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one is a CDK4/6 inhibitor that blocks the activity of these enzymes and inhibits cell proliferation. The compound has been shown to inhibit the growth of cancer cells in vitro. It also inhibits the growth of squamous carcinoma cells, but not normal epithelial cells, in a hypoxic tumor model in vivo. The mechanism of action is thought to be via the suppression of suppressor genes such as BCR/ABL kinase and epidermal growth factor receptor (EGFR).